Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
56 hedge funds and large institutions have $222M invested in Kindred Biosciences, Inc. in 2014 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 26 increasing their positions, 3 reducing their positions, and 6 closing their positions.
767% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 3
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
44% more funds holding
Funds holding: 39 → 56 (+17)
41% more capital invested
Capital invested by funds: $157M → $222M (+$64.7M)
17.27% more ownership
Funds ownership: 43.01% → 60.29% (+17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.5M |
| 2 |
Jennison Associates
New York
|
+$10.2M |
| 3 |
DM
Deerfield Management
New York
|
+$6.37M |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$3.48M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$2.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TG
TCW Group
Los Angeles,
California
|
-$1.82M |
| 2 |
SIM
Spark Investment Management
New York
|
-$339K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$244K |
| 4 |
PP
PDT Partners
New York
|
-$217K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$155K |
KIN Hedge Fund Activity: Q2 2014 in Review
56 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q2 2014, worth a combined $222M — up 41% from $157M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new KIN positions and 6 closed out — a net gain of 17 holders — while 26 added to existing stakes and 3 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $13.5M. The largest seller was TCW Group, exiting entirely with an estimated $1.82M sold.
- 56 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q2 2014, up from 39 in Q1 2014.
- Funds reported $222M of Kindred Biosciences, Inc. stock for Q2 2014, up 41% quarter-over-quarter.
- 23 funds opened new Kindred Biosciences, Inc. positions in Q2 2014 and 6 closed out, a net change of +17 holders.
- The largest Kindred Biosciences, Inc. buyer in Q2 2014 was Fidelity Investments, an estimated $13.5M added.
- The largest Kindred Biosciences, Inc. seller in Q2 2014 was TCW Group, an estimated $1.82M sold.
Based on aggregated 13F filings for Q2 2014.